Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions
- PMID: 32843909
- PMCID: PMC7429585
- DOI: 10.1007/s13167-020-00214-1
Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions
Abstract
In the early twenty-first century, societies around the world are facing the paradoxal epidemic development of PCa as a non-communicable disease. PCa is the most frequently diagnosed cancer for men in several countries such as the USA. Permanently improving diagnostics and treatments in the PCa management causes an impressive divergence between, on one hand, permanently increasing numbers of diagnosed PCa cases and, on the other hand, stable or even slightly decreasing mortality rates. Still, aspects listed below are waiting for innovate solutions in the context of predictive approaches, targeted prevention and personalisation of medical care (PPPM / 3PM).A.PCa belongs to the cancer types with the highest incidence worldwide. Corresponding economic burden is enormous. Moreover, the costs of treating PCa are currently increasing more quickly than those of any other cancer. Implementing individualised patient profiles and adapted treatment algorithms would make currently too heterogeneous landscape of PCa treatment costs more transparent providing clear "road map" for the cost saving.B.PCa is a systemic multi-factorial disease. Consequently, predictive diagnostics by liquid biopsy analysis is instrumental for the disease prediction, targeted prevention and curative treatments at early stages.C.The incidence of metastasising PCa is rapidly increasing particularly in younger populations. Exemplified by trends observed in the USA, prognosis is that the annual burden will increase by over 40% in 2025. To this end, one of the evident deficits is the reactive character of medical services currently provided to populations. Innovative screening programmes might be useful to identify persons in suboptimal health conditions before the clinical onset of metastasising PCa. Strong predisposition to systemic hypoxic conditions and ischemic lesions (e.g. characteristic for individuals with Flammer syndrome phenotype) and low-grade inflammation might be indicative for specific phenotyping and genotyping in metastasising PCa screening and disease management. Predictive liquid biopsy tests for CTC enumeration and their molecular characterisation are considered to be useful for secondary prevention of metastatic disease in PCa patients.D.Particular rapidly increasing PCa incidence rates are characteristic for adolescents and young adults aged 15-40 years. Patients with early onset prostate cancer pose unique challenges; multi-factorial risks for these trends are proposed. Consequently, multi-level diagnostics including phenotyping and multi-omics are considered to be the most appropriate tool for the risk assessment, prediction and prognosis. Accumulating evidence suggests that early onset prostate cancer is a distinct phenotype from both aetiological and clinical perspectives deserving particular attention from view point of 3P medical approaches.
Keywords: 3PM); Adapted treatment algorithms; Adolescence; Aetiology; Age; Aggressive metastatic disease; Alcohol consumption; Androgen dependent; Apoptosis resistance; Biomarker patterns; Body mass index BMI; Bone-specific alkaline phosphatase; C-index; Castration resistant; Choline; Circulating tumour cells (CTC); Coffee; Comorbidities; Curcumin; Diet; Disease manifestation; Economy; Elderly; Ellargic acid; Ethics; Ethnicity; Family history; Fish; Folate; Fruits; Garlic; Genetic; Green tea; Gut microbiota; Human development index; Hybrid imaging; Incidence; Indicator; Individualised patient profile; Inflammation; Insulin-like growth factor; Ischemic lesions; Lactate dehydrogenase; Life quality; Lifestyle; Liquid biopsy; Lycopene; Malignancy; Meat; Microcirculation; Modifiable risk factors; Mortality; Multi-factorial systemic disease; Multi-omics; Multi-parametric analysis; Obesity; Oxidative stress; PET/MRI; PSA screening; Patient stratification; Personalised nutrition; Physical activity; Prebiotics; Predictive preventive personalised medicine (PPPM; Probiotics; Prognosis; Prostate cancer (PCa); Prostate cancer antigen 3; Quercetin; Race; Radical prostatectomy; Risk assessment; Roadmap; Saturated fat; Selenium/selenite; Sexually transmitted diseases; Sleep disorders; Smoking; Socio-economic factors; Stillbenes; Sulphorapane; Survival; Systemic hypoxic condition; Toxic environment; Trace elements; Transrectal ultrasound; Trends; Urinary tract infection; Urology; Vasectomy; Vegetables; Vitamins A, C, D, E, and K; Young population; miRNA.
© The Author(s) 2020.
Conflict of interest statement
Competing interestThe authors declare that they have no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7429585/bin/13167_2020_214_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7429585/bin/13167_2020_214_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7429585/bin/13167_2020_214_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7429585/bin/13167_2020_214_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7429585/bin/13167_2020_214_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7429585/bin/13167_2020_214_Fig6_HTML.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7429585/bin/13167_2020_214_Fig7_HTML.gif)
Similar articles
-
The paradigm change from reactive medical services to 3PM in ischemic stroke: a holistic approach utilising tear fluid multi-omics, mitochondria as a vital biosensor and AI-based multi-professional data interpretation.EPMA J. 2024 Feb 27;15(1):1-23. doi: 10.1007/s13167-024-00356-6. eCollection 2024 Mar. EPMA J. 2024. PMID: 38463624 Free PMC article.
-
Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper.Cancers (Basel). 2022 Jan 28;14(3):675. doi: 10.3390/cancers14030675. Cancers (Basel). 2022. PMID: 35158943 Free PMC article. Review.
-
Ischemic stroke of unclear aetiology: a case-by-case analysis and call for a multi-professional predictive, preventive and personalised approach.EPMA J. 2022 Nov 17;13(4):535-545. doi: 10.1007/s13167-022-00307-z. eCollection 2022 Dec. EPMA J. 2022. PMID: 36415625 Free PMC article.
-
Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine - comprehensive effects of phytochemicals in primary, secondary and tertiary care.EPMA J. 2022 Jul 8;13(3):461-486. doi: 10.1007/s13167-022-00288-z. eCollection 2022 Sep. EPMA J. 2022. PMID: 35821883 Free PMC article. Review.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
Cited by
-
Frailty mediating the causality between leucocyte telomere length and mortality: a cohort study of 440,551 UK Biobank participants.EPMA J. 2024 Feb 15;15(1):99-110. doi: 10.1007/s13167-024-00355-7. eCollection 2024 Mar. EPMA J. 2024. PMID: 38463625
-
CVD phenotyping in oncologic disorders: cardio-miRNAs as a potential target to improve individual outcomes in revers cardio-oncology.J Transl Med. 2024 Jan 12;22(1):50. doi: 10.1186/s12967-023-04680-9. J Transl Med. 2024. PMID: 38216965 Free PMC article. Review.
-
Gene methylation status in focus of advanced prostate cancer diagnostics and improved individual outcomes.Transl Androl Urol. 2023 Dec 31;12(12):1813-1826. doi: 10.21037/tau-23-405. Epub 2023 Dec 14. Transl Androl Urol. 2023. PMID: 38196695 Free PMC article.
-
The potential preventive effect of dietary phytochemicals In Vivo.BDJ Open. 2023 Jul 18;9(1):30. doi: 10.1038/s41405-023-00157-5. BDJ Open. 2023. PMID: 37463912 Free PMC article.
-
Inflammation-related indicators have a potential to increase overall quality of the prostate cancer management: a narrative review.Transl Androl Urol. 2023 May 31;12(5):809-822. doi: 10.21037/tau-23-55. Epub 2023 May 8. Transl Androl Urol. 2023. PMID: 37305618 Free PMC article. Review.
References
-
- Golubnitschaja O, Raj Dahal A. Prostate cancer: decreasing age, increasing incidence of metastatic disease and high CTC potential prompts the paradigm shift from reactive to predictive, preventive and personalised medicine in disease management. EPMA J. 2020. 10.1007/s13167-020-00206-1.
-
- GLOBOCAN 2018, https://www.uicc.org/news/new-global-cancer-data-globocan-2018, Accessed on April 27th 2020.
-
- Ballar Kirmizibayrak P, Erbaykent-Tepedelen B, Gozen O, Erzurumlu Y. Divergent Modulation of Proteostasis in Prostate Cancer. Adv Exp Med Biol. 2020. 10.1007/978-3-030-38266-7_5. - PubMed
-
- Ihle CL, Owens P. Integrating the immune microenvironment of prostate cancer induced bone disease. Mol Carcinog. 2020. 10.1002/mc.23192. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous